0QLQ Stock Overview
Develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0QLQ from our risk checks.
Ypsomed Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 416.00 |
| 52 Week High | CHF 438.50 |
| 52 Week Low | CHF 243.50 |
| Beta | 0.97 |
| 11 Month Change | 0.23% |
| 3 Month Change | 0.85% |
| 1 Year Change | 63.78% |
| 33 Year Change | 176.96% |
| 5 Year Change | 202.77% |
| Change since IPO | 181.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QLQ | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -2.7% | 1.0% | 0.03% |
| 1Y | 63.8% | 10.1% | 8.5% |
Return vs Industry: 0QLQ exceeded the UK Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: 0QLQ exceeded the UK Market which returned 8.5% over the past year.
Price Volatility
| 0QLQ volatility | |
|---|---|
| 0QLQ Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QLQ has not had significant price volatility in the past 3 months.
Volatility Over Time: 0QLQ's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,296 | Simon Michel | www.ypsomed.com |
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates through two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, and wearable injectors, as well as other smart devices.
Ypsomed Holding AG Fundamentals Summary
| 0QLQ fundamental statistics | |
|---|---|
| Market cap | CHF 5.62b |
| Earnings (TTM) | CHF 78.37m |
| Revenue (TTM) | CHF 548.46m |
71.8x
P/E Ratio10.3x
P/S RatioIs 0QLQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QLQ income statement (TTM) | |
|---|---|
| Revenue | CHF 548.46m |
| Cost of Revenue | CHF 359.40m |
| Gross Profit | CHF 189.05m |
| Other Expenses | CHF 110.69m |
| Earnings | CHF 78.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 13, 2024
| Earnings per share (EPS) | 5.74 |
| Gross Margin | 34.47% |
| Net Profit Margin | 14.29% |
| Debt/Equity Ratio | 41.4% |
How did 0QLQ perform over the long term?
See historical performance and comparison